It should give you a clearer understanding of your body, a realistic path forward, and a provider relationship that supports you as your needs evolve
Phase 3 trials (Frias et al., 2021
1.7 mg (weeks 1316): Significant appetite suppression for most patients
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
The reduction in LFC was significantly correlated ( p 0.0006) with baseline LFC ( = 0.71), reductions in visceral adipose tissue (VAT) ( = 0.29), reductions in the transaminase liver enzyme ASAT ( = 033), and reductions in body weight ( p = 034) in the tirzepatide groups (79)
During maintenance, once you have reached your target dose and your weight loss has stabilized, timing flexibility increases